Engineered immune cells take on liver cancer in early trial
Disease control
Recruiting now
This early-phase trial is testing a new treatment for advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, which are genetically modified to recognize and attack cancer cells that produce a protein called AFP. Twelve…
Phase: PHASE1 • Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC